Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia

Basit Öğe Kaydı
dc.contributor.authorAljunid, Syed
dc.contributor.authorMaimaiti, Namaitijiang
dc.contributor.authorNur, Amrizal M.
dc.contributor.authorNoor, Mohd Rushdan Md
dc.contributor.authorPuteh, Sharifa Ezat Wan
dc.date.accessioned2024-02-23T14:27:18Z
dc.date.available2024-02-23T14:27:18Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractBackground: The HPV vaccine was introduced to Malaysian national immunization programme in 2010. The current implementation age of HPV vaccination in Malaysian is at the age of 13 years school girls, given according to a 3 doses protocol which may complicate implementation and compliance. Aim of the study is to determine the cost-effectiveness of HPV vaccination regime comparing twice versus thrice HPV vaccinations dose regime among adolescent girls in Malaysia. Methods: A Markov cohort model reflecting the natural history of HPV infection accounting for oncogenic and low-risk HPV was adapted for 13 year old Malaysian girls cohort (n = 274,050). Transition probabilities, utilities values, epidemiological and cost data were sourced from published literature and local data. Vaccine effectiveness was based on overall efficacy reported from 3-doses clinical trials, with the assumption that the 2-doses is non-inferior to the 3-doses allowing overall efficacy to be inferred from the 3-doses immunogenicity data. Price parity and life-long protection were assumed. The payer perspective was adopted, with appropriate discounting for costs (3 %) and outcomes (3 %). One way sensitivity analysis was conducted. The sensitivity analysis on cost of vaccine, vaccine coverage and discount rate with a 2-doses protocol was performed. Result: The 3-doses and 2-doses regimes showed same number of Cervical Cancers averted (361 cases); QALYs saved at 7,732,266. However, the lifetime protection under the 2-doses regime, showed a significant cost-savings of RM 36, 722,700 compared to the 3-doses scheme. The MOH Malaysia could vaccinate 137,025 more girls in this country using saving 2-doses regime vaccination programme. The model predicted that 2-doses HPV vaccination schemes can avoid additional 180 Cervical Cancers and 63 deaths compare to 3-doses. Conclusion: A 2-doses HPV vaccination scheme may enable Malaysian women to be protected at a lower cost than that achievable under a 3-doses scheme, while avoiding the same number of Cervical Cancer cases and deaths. Using the saving money with 2-doses, more Cervical Cancers and deaths can be avoided.en_US
dc.description.sponsorshipGlaxoSmithKline Pty Ltden_US
dc.description.sponsorshipThis study was approved by MOH Malaysia and National University Malaysia Medical Center. The study was funded by GlaxoSmithKline Pty Ltd.en_US
dc.identifier.doi10.1186/s12889-016-2754-1
dc.identifier.issn1471-2458
dc.identifier.pmid26803814en_US
dc.identifier.scopus2-s2.0-84979052677en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1186/s12889-016-2754-1
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14541
dc.identifier.volume16en_US
dc.identifier.wosWOS:000368489600002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBiomed Central Ltden_US
dc.relation.ispartofBmc Public Healthen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHpven_US
dc.subjectVaccineen_US
dc.subject3-Dosesen_US
dc.subject2-Dosesen_US
dc.subjectSchoolgirlsen_US
dc.subjectMalaysian Girlsen_US
dc.titleCost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu